date,title,source
Oct-18-18,Retrophin to Report Third Quarter 2018 Financial Results,GlobeNewswire
Oct-19-18,"New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin  Factors of Influence, Major Initiatives and Sustained Production",GlobeNewswire
Oct-25-18,Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology,GlobeNewswire
Oct-26-18,Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis,GlobeNewswire
Oct-29-18,"Robbins Arroyo LLP Is Investigating the Officers and Directors of Retrophin, Inc. (RTRX) on Behalf of Shareholders",Business Wire
Nov-01-18,"Retrophin (RTRX) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-01-18,Retrophin: 3Q Earnings Snapshot,Associated Press
Nov-01-18,Retrophin Reports Third Quarter 2018 Financial Results,GlobeNewswire
Nov-07-18,Edited Transcript of RTRX earnings conference call or presentation 1-Nov-18 8:30pm GMT,Thomson Reuters StreetEvents
Nov-07-18,Retrophin to Present at the Jefferies 2018 London Healthcare Conference,GlobeNewswire
Nov-08-18,Edited Transcript of RTRX earnings conference call or presentation 1-Nov-18 8:30pm GMT,Thomson Reuters StreetEvents
Nov-08-18,Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript,Motley Fool
Nov-28-18,Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference,GlobeNewswire
Nov-28-18,"Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International  Future Expectations, Projections Moving into 2018",GlobeNewswire
Dec-14-18,Retrophin Inc (RTRX) Hedge Funds Are Snapping Up,Insider Monkey
Dec-20-18,Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN,GlobeNewswire
Dec-27-18,Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy,GlobeNewswire
